ICER Issues Final Report on Spinraza and Zolgensma, Provides Policy Recommendations Related to Pricing and Coverage of Treatments for Spinal Muscular Atrophy

-- Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes unanimously that price for Spinraza is too high to align fairly with these benefits, and urges fair pricing for emerging gene therapy Zolgensma to support sustainable access to innovation --

Read More